Related Experiment Videos
Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction
1Department of Cardiovascular Medicine, Northwick Park & St Mark's NHS Trust Hospital, Harrow, United Kingdon.
Insights
Early administration of carvedilol, a beta-blocker, significantly reduces left ventricular remodeling after myocardial infarction in patients with heart dysfunction. This treatment helps prevent adverse changes in heart structure and function.
Area of Science:
- Cardiology
- Pharmacology
- Medical Research
Background:
- Left ventricular remodeling is a significant complication following acute myocardial infarction (AMI).
- Persistent left ventricular dysfunction post-AMI increases the risk of adverse cardiac events.
- Vasodilating nonselective beta-blockers like carvedilol are investigated for their potential to mitigate post-MI cardiac damage.
Purpose of the Study:
- To evaluate the impact of carvedilol on left ventricular remodeling indexes in patients with left ventricular dysfunction after AMI.
- To determine if early carvedilol treatment can attenuate adverse structural changes in the left ventricle.
Main Methods:
- A double-blind, randomized, placebo-controlled study involving 49 patients with left ventricular ejection fraction <45% post-AMI.
- Patients received carvedilol or placebo for 6 months, initiated after thrombolysis.
- Two-dimensional echocardiography was used to assess left ventricular remodeling parameters at baseline and 3 months post-AMI.
Main Results:
- Carvedilol significantly reduced wall thickness opposite the infarct site (P=.01) and left ventricular mass (P=.02).
- Carvedilol prevented the detrimental alteration of the sphericity index (P=.02) and wall thickening abnormality at the infarct site (P=.002).
- These changes indicate a significant attenuation of left ventricular remodeling in the carvedilol group.
Conclusions:
- Early administration of carvedilol after acute myocardial infarction attenuates left ventricular remodeling.
- Carvedilol is effective in patients with persistent left ventricular dysfunction identified before hospital discharge.
- The findings support the use of carvedilol to improve cardiac structure and function post-MI.
Objective:
The aim of the study was to assess the effects of carvedilol, a vasodilating nonselective beta-blocker, on the indexes of left ventricular remodeling after acute myocardial infarction in those with left ventricular dysfunction.
Methods And Results:
Forty-nine patients with predischarge left ventricular ejection fraction <45% after acute myocardial infarction were evaluated in a double-blind, randomized, placebo-controlled, parallel group study (selected from the database of the Carvedilol Heart Attack Pilot Study: CHAPS). Patients received medication after thrombolysis and continued to do so for 6 months. Two-dimensional echocardiography was performed before discharge (7 to 10 days after admission) and at 3 months after acute myocardial infarction. Analysis of variance showed that wall thickness opposite the site of infarction decreased from (mean +/- SD) 12.3 +/- 2.1 mm to 11.0 +/- 2.4 mm with carvedilol compared with 11.6 +/- 1.9 mm to 12.2 +/- 1.9 mm with placebo (P =.01). Left ventricular mass changed from 235 +/- 74 g to 217 +/- 64 g with carvedilol compared with 227 +/- 80 g to 252 +/- 85 g with placebo ( P =.02). Carvedilol prevented alteration of sphericity index (ratio of long and short axis of left ventricle) that changed from 1.65 +/- 0.29 to 1.66 +/- 20 with carvedilol compared with 1.58 +/- 0.33 to 1.39 +/- 0.19 with placebo (P =.02); alteration was also prevented of wall thickening abnormality at infarct site, which changed from 9.2 +/- 3.1 cm2 to 9.1 +/- 3.5 cm 2 with carvedilol compared with 10.3 +/- 3.3 cm2 to 13.5 +/- 4.6 cm2 with placebo (P =.002).
Conclusion:
Carvedilol administered early after acute myocardial infarction results in attenuation of left ventricular remodeling in patients with persistent left ventricular dysfunction before discharge.